Company intelligence / Profile preview
Meridian Laboratories
Buffalo Grove, Illinois, United Statesmeridian-lab.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ML141 (docetaxel injectable, improved formulation) received U.S. FDA approval in 2022; proprietary PARP+ATR dual inhibitor is in development targeting prostate and potentially other cancers; improved cabazitaxel formulation is also reported in pipeline.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeImproved formulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Apobiologix (division of Apotex), for development/marketing of docetaxel improved formulation
Beyond the preview
Go deeper on Meridian Laboratories.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meridian Laboratories.